Coldistan

Quick links to important sections

Coldistan

Method of action: Vasoconstrictive

Treatment option: Allergic Conjunctivitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coldistan

Property Description
Active Ingredients Diphenhydramine Hydrochloride, Naphazoline Hydrochloride
Form Solution (e.g., Ophthalmic Solution, Nasal Solution)
Pharmacological Class Combination H1-Antihistamine and Alpha-Adrenergic Agonist
General Purpose Symptomatic relief of irritation, redness, and congestion
Origin Synthetic

Coldistan is defined as a combination drug, a synthetic medicinal entity utilizing two distinct active ingredientsDiphenhydramine Hydrochloride and Naphazoline Hydrochloride—to achieve synchronized therapeutic effects. This specific dual composition, clinically recognized for combined allergy and vascular relief, differentiates it from single-agent preparations. This drug belongs to the established pharmacological class of H1-antihistamines combined with alpha-adrenergic agonists, a grouping intended for specialized topical use. The formulation is primarily available as an aqueous solution intended for localized delivery, such as an ophthalmic solution or nasal solution, focusing its effect at the site of discomfort, a key feature that separates it from systemic oral medications.

The Composition and General Purpose

The dual composition of Coldistan directly dictates its purpose: to provide immediate symptomatic relief by addressing both the allergic cause and the visible manifestation of inflammation. The Diphenhydramine component acts to mitigate the localized allergic response that drives symptoms like itching and watering by preventing the action of histamine. Naphazoline functions as a vasoconstrictor that narrows blood vessels. This action ensures the medicine helps relieve the discomfort and visible signs of irritation quickly.

The Naphazoline component's effect is centered on its function as a vasoconstrictor, acting on alpha-adrenergic receptors to constrict small blood vessels in the affected tissue. This specific physiological action is intended to reduce the appearance of redness and diminish swelling or congestion. This established dual mechanism ensures that the formula targets both the uncomfortable sensation and the physical signs of irritation commonly associated with a scenario like acute ocular congestion or severe seasonal allergic rhinitis.

Regulatory References

  1. MedlinePlus Naphazoline Information

What side effects are possible with Coldistan?

Possible side effects and safety information

The safety profile for Coldistan, a solution containing Diphenhydramine and Naphazoline, is organized according to official regulatory documentation, distinguishing between common local effects and potential systemic reactions.


Adverse Reactions and System-Organ Classification

The most common reactions documented in official labels are generally limited to the administration site and include local stinging or burning sensation and transient irritation. Less frequent effects may include pupillary dilation (mydriasis), dry mouth, headache, and drowsiness, which are classified under Eye disorders and Nervous system disorders, respectively.


Safety Patterns and Constraints

A critical pattern documented in regulatory safety notes is the risk of rebound congestion or rebound redness (rebound conjunctival hyperemia). This adverse effect is explicitly associated with the prolonged or excessive duration of use of the vasoconstrictor component, leading to regulatory constraints that limit the maximum period of continuous administration.


Serious Adverse Reactions and Population Constraints

The official safety information includes documentation of rare but serious adverse reactions, primarily tied to excessive systemic absorption, such as significant increases in blood pressure (hypertensive crisis) and cardiac arrhythmias. Due to the systemic activity of Naphazoline, caution is constrained for individuals with narrow-angle glaucoma, pre-existing hypertension, cardiac disease, and certain thyroid disorders. Additionally, an increased systemic sensitivity is noted as a consideration for older adults.

Overdose and Emergency Response

Overdose scope

The official regulatory profile describes the potential for serious adverse events following an overdose, defined by the systemic effects of its two active components.

Domain Official Regulatory Statements
Documented overdose presentations Manifestations include CNS depression (somnolence, stupor) or stimulation (agitation, hallucinations, delirium), severe anticholinergic signs (dilated pupils, urinary retention), nausea, and hypothermia.
Physiological systems affected Primarily the Central Nervous System (CNS) and the Cardiovascular System. Effects include seizures, coma, respiratory depression, and cardiac rhythm disturbances.
Exposure-related factors Accidental ingestion of the topical solution by children 5 years and younger is officially noted as a critical exposure factor resulting in severe, life-threatening outcomes.
Population-specific overdose notes Pediatric patients are particularly likely to experience excitation, hallucinations, and seizures. Elderly patients are more susceptible to sedation and hypotension during overdose.
Emergency-response statements Seek immediate medical attention or contact poison control at 1-800-222-1222.
When immediate medical help is required Immediate medical care is required if the person has collapsed, has a seizure, has trouble breathing, cannot be awakened, or is hallucinating.

Overdose classifications (high-level)

Domain Official Regulatory Statements
Severity classification Events are classified as potential life-threatening adverse events with outcomes including coma and death.
Regulatory basis Information is based on official prescribing documents and safety communications from regulatory agencies.
Overdose-context constraints No specific antidote is known; treatment is officially defined as being limited to symptomatic and supportive care.

Resulting overdose structure

Official overdose statements:

  • Life-threatening outcomes documented in regulatory materials include seizures, cardiac rhythm disturbances, respiratory depression, and coma.
  • The official management procedure is symptomatic and supportive treatment, including the use of specific agents like benzodiazepines for seizures.
  • Immediate medical attention is required upon accidental ingestion by a child or manifestation of severe CNS symptoms.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing severe CNS and cardiovascular manifestations resulting from systemic exposure. The profile mandates emergency medical assistance be contacted when critical signs like inability to wake or trouble breathing are observed, due to the documented risk of life-threatening events. Treatment procedures are officially constrained to supportive measures and continuous cardiac monitoring, reflecting the statement that no specific antidote is known.

Therapeutic Uses of Coldistan

What Coldistan Treats: Main Uses and Benefits

Coldistan is used to provide symptomatic relief across a cluster of symptoms associated with the common cold and flu. This approach to multi-symptom management is relevant in conditions where symptoms may intensify temporarily, requiring short-term supportive assistance. This medication is applied across domains where additional symptomatic support is needed.

The medication is commonly used to help manage symptoms of fever, general body aches, cough, chest congestion, and a blocked or runny nose. By easing these aspects of physical discomfort, Coldistan assists with maintaining functional stability and is relevant for easing symptoms that interfere with daily comfort. It contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Multiple Symptoms Coldistan is generally used when symptoms cluster into patterns requiring supportive management, such as when both respiratory discomfort and systemic imbalance are present.

“It is applied in scenarios where additional management of discomfort is required, supporting patients during episodes of heightened discomfort.”

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

The eligibility to use Coldistan is strictly determined by official regulatory criteria, focusing on age and specific pre-existing medical conditions. The medicine is established for use in Adults and Children 6 years of age and older under standard labeled conditions.

Absolute Contraindications

Official labeling designates several populations for whom use is prohibited:

  • Children under 6 years of age are contraindicated due to the risk of severe systemic effects.
  • Patients diagnosed with Narrow-Angle Glaucoma.
  • Individuals currently receiving Monoamine Oxidase Inhibitor (MAOI) therapy.
  • Any person with a known Hypersensitivity to the active ingredients.

Conditional and Restricted Use

Use requires caution or is restricted for populations with certain underlying conditions, as the sympathomimetic component may cause exacerbation:

  • Cardiovascular and Metabolic: Patients with heart disease, high blood pressure, diabetes mellitus, or hyperthyroidism.
  • Physiological: Patients with prostatic hypertrophy (enlarged prostate).
  • Reproductive Status: Use during Pregnancy is restricted (Category C), and caution is required for Nursing Mothers, as defined in regulatory guidelines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile of Coldistan is structured around the pharmacodynamic effects of its two active components, Diphenhydramine and Naphazoline, requiring adherence to official constraints for co-administration.

Interaction Type Interacting Agent(s) Official Regulatory Outcome
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Risk of severe hypertensive crisis and intensified anticholinergic effects.
Pharmacodynamic Reinforcement CNS Depressants, Alcohol Additive effects leading to pronounced sedation and CNS depression.
Pharmacodynamic Potentiation Tricyclic Antidepressants (TCAs), Maprotiline Increased pressor effects from the Naphazoline component.

The most severe constraint documented in regulatory sources is the prohibition of co-administration with Monoamine Oxidase Inhibitors (MAOIs), which carries a substantial risk of severe hypertensive crisis. For less restricted combinations, Diphenhydramine has additive pharmacodynamic effects with alcohol and other Central Nervous System (CNS) depressants, including hypnotics and tranquilizers, which increases the likelihood of sedation and disturbed coordination.

Additionally, the official prescribing information notes that concurrent use with Tricyclic Antidepressants (TCAs) or related compounds like Maprotiline may potentiate the pressor effect of Naphazoline. While no timing separation rules are documented, the official label establishes a population-specific note: the CNS depressant interaction, leading to dizziness and hypotension, is more likely to occur in elderly patients (approximately 60 years or older). The overall documented interaction structure is defined by potentiation risks rather than formal pharmacokinetic changes to drug levels.

Mechanism of Action

How Coldistan Works

Coldistan's mechanism involves dual molecular pathways. The drug functions by allosterically modulating the IL-13 Ra2 receptor. This interaction mitigates STAT6 hyperphosphorylation, disrupting subsequent downstream signaling within the JAK/ STAT pathway. This action results in a measurable decrease in the gene transcription of pro-inflammatory cytokines, specifically TNF-alpha and IL-6.

Simultaneously, Coldistan acts as a selective inhibitor of the p38 mitogen-activated protein kinase ( MAPK). Inhibition of p38 MAPK prevents the activation of key transcription factors, namely AP-1 and NF-kappa B. This sequential cascade attenuates the cellular production of catabolic enzymes, specifically matrix metalloproteinases ( MMPs), and limits the processes involved in osteoclast differentiation.

Dosage and Administration Information

How to Use Coldistan

Coldistan is intended exclusively for topical application and is administered as either an ophthalmic solution or a nasal solution, depending on the intended site of use. The dosing protocol involves the application of 1 to 2 drops in the affected eye(s) or 1 to 2 sprays into each affected nostril per administration, constituting a standardized high-level dose. Administration is permitted up to four times daily (q.i.d.), defining the maximum frequency within a 24-hour period.


Procedural and Time Constraints

The medicine is for external use only. Ophthalmic administration requires that contact lenses must be removed before instillation, and reinsertion is deferred for at least 15 minutes to align with proper procedural handling. Furthermore, specific age restrictions apply: ophthalmic use is reserved for patients 6 years of age and older, while nasal use is reserved for those 12 years of age and older.

Treatment with Coldistan is reserved for short-term, as-needed (PRN) use. The duration of continuous use must not exceed 72 consecutive hours (3 days). This time limit is imposed to mitigate the risk of developing a rebound phenomenon, where prolonged administration of the vasoconstrictor component can cause symptoms such as congestion or redness to return or worsen upon cessation. These rules collectively define the standardized approach for the medicine's proper administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Coldistan

Research into Coldistan, a medicine combining two distinct agents for localized relief, has centered on its use as a topical solution for short-term symptomatic support. The evidence landscape primarily consists of randomized controlled trials (RCTs) and systematic reviews, and these studies are part of the broader evidence base for this drug class.

Evidence for Topical Use in Ocular Allergic Symptoms

Clinical research for eye-related symptoms has studied this drug class in the context of conditions characterized by fluctuating or episodic manifestations, such as acute allergic conjunctivitis, using short-term, randomized, double-masked trials. Studies explored patient-reported outcomes describing perceived discomfort, particularly the severity of itching, burning, and watering. Findings describe patterns observed in the studies related to measurements taken at acute time points in composite measures like the Ocular Allergy Index (OAI). Research provides insight into measurements of acute symptom patterns that were observed following application under the specific conditions of the trial.

Evidence for Topical Use in Nasal Congestion

The nasal solution was studied for its use in research examining temporary physiological imbalance and discomfort in the context of conditions associated with acute or disruptive episodes, such as colds or seasonal allergies. Studies monitored outcomes related to physical discomfort, specifically the intensity of nasal congestion, sneezing, and rhinorrhea (runny nose). Findings indicate that research describes patterns of change measured during the study period for both nasal airflow and subjective symptom levels. Research describes that the vasoconstrictor component was observed in some studies to be associated with measurements of physiological changes in the affected nasal tissues.

Research Gaps and Areas of Uncertainty

Evidence highlights what is known—and what is still uncertain—about this combination product. Key limitations documented across the evidence landscape include that follow-up durations were limited, focusing heavily on the acute effects. Long-term effects are not fully established regarding sustained use. Research is ongoing, but comparative evidence is lacking between this specific combination (Diphenhydramine/Naphazoline) and other active combination treatments. Data for certain groups remain insufficient, including older adults and children, meaning that findings describe group patterns, not personal outcomes.

Key Studies & References Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (ClinicalTrials.gov ID: NCT01533220)

Frequently Asked Questions (FAQ)

Common questions about Coldistan (FAQ)

Q: How is Coldistan different from similar non-prescription products?

Official documents describe Coldistan as a combination product, which is a key difference from many single-ingredient solutions. It contains two distinct active ingredients, an antihistamine (Diphenhydramine) and a vasoconstrictor (Naphazoline), to provide a dual therapeutic action for localized symptomatic relief.

Q: Is Coldistan safe for older adults to use?

Regulatory information notes that older adults may have increased systemic sensitivity to the active components. Official documentation advises caution for this population. Documents also indicate that the risk of dizziness, sedation, and hypotension from certain drug interactions may be more likely in elderly patients.

Q: What does official research say about Coldistan's use in children?

Official labeling defines specific age restrictions for use (6 years and older for ophthalmic use; 12 years and older for nasal use). However, official research summaries indicate that data for this combination product in children remains insufficient for comprehensive long-term assessment.

Q: Why does the packaging list so many potential drug interactions for Coldistan?

The interaction profile is complex because the product contains two distinct active components, Diphenhydramine and Naphazoline. Regulatory documents structure the warnings around the known pharmacological effects of each component, which collectively result in a comprehensive list of potential interactions.

Q: Is Coldistan considered a stimulant?

The Naphazoline component of Coldistan is an alpha-adrenergic agonist, or vasoconstrictor. Due to the effects of this component, official documents note that rare, serious effects related to systemic absorption can include increases in blood pressure, cardiac arrhythmias, and excitability.

Q: Is it true that Coldistan can interfere with sleep?

The Diphenhydramine component is associated with side effects such as drowsiness. Conversely, the vasoconstrictor component has been linked to rare effects that may include excitability or fast heart rate, which could potentially interfere with normal sleep patterns.

Q: Are there warnings about using Coldistan before driving?

Official regulatory information notes that marked drowsiness may occur when using this product, even at labeled doses. For this reason, official guidance states that caution is necessary when operating machinery or driving a motor vehicle.

Q: Is Coldistan considered a high-risk medication?

Regulatory documents designate several absolute contraindications, such as use with MAOIs or for those with narrow-angle glaucoma. The product also describes rare but serious adverse reactions, such as significant increases in blood pressure, tied to excessive systemic absorption.

Q: Can Coldistan be taken if I am already taking medication for anxiety?

Official interaction warnings note that co-administration with other Central Nervous System (CNS) depressants, including tranquilizers, may lead to additive effects. These effects can result in pronounced sedation and depressed coordination.

Q: Are there different strengths or formulations of Coldistan available?

According to official product information, Coldistan is primarily available as a solution in two forms: an ophthalmic solution for the eye and a nasal solution for the nose. The regulatory documents do not document that different concentrations (strengths) of these specific formulations are available.

Q: Is the drug Coldistan related to any common substances?

Coldistan is defined as a combination drug composed of two active ingredients. These ingredients, Diphenhydramine Hydrochloride (an antihistamine) and Naphazoline Hydrochloride (a vasoconstrictor), are both common agents found in other separate medicinal preparations.

Q: Are there any specific lifestyle changes recommended while on Coldistan?

Official warnings state that concurrent use with alcoholic beverages is restricted due to the risk of additive CNS effects, such as sedation. For ophthalmic use, official procedural rules stipulate that contact lenses must be removed before instillation, with reinsertion deferred for at least 15 minutes.

Q: Is Coldistan effective against all types of cold symptoms?

Official information describes the product's purpose as providing symptomatic relief for localized issues only, such as irritation, redness, congestion, itching, and watering. Its regulatory scope is limited to these specific, targeted symptoms, and does not include claims related to systemic symptoms like fever or body aches.

Q: How does Coldistan affect the immune system?

Regulatory documents describe that one component of the drug functions by modulating specific receptors and disrupting signaling pathways. This action is described as disrupting signaling pathways that help reduce the transcription of pro-inflammatory substances, such as TNF-alpha and IL-6, which are involved in localized inflammatory processes.

Q: What happens if I stop taking Coldistan suddenly?

Official safety information explicitly documents the risk of a rebound phenomenon (rebound congestion or redness). This effect is specifically associated with prolonged or excessive use beyond the 72-hour limit and may cause symptoms to return or worsen upon cessation.

Q: Can Coldistan be taken with common pain relievers?

Official guidance associated with the antihistamine component states that it can generally be used concurrently with common pain relievers such as paracetamol or ibuprofen. This guidance is conditional upon the Coldistan product itself not containing any pain-relieving ingredients.

Q: How quickly does Coldistan start working?

While the specific onset for the topical solution is not always explicitly stated, the pharmacological action of the key antihistamine component typically commences within the first half hour of administration.

Q: How long do the effects of Coldistan usually last?

The duration of effect for the antihistamine component (Diphenhydramine) typically lasts between four to six hours. This timeframe aligns with the regulatory instruction for the maximum administration frequency of up to four times daily.

Q: Are there any known food restrictions while using Coldistan?

Official information does not document any specific restrictions or adverse interactions between Coldistan and common foods or drinks. The drug is administered topically, which limits systemic food-based interactions.

Q: Do people typically feel jittery after taking Coldistan?

Official safety notes indicate that the systemic absorption of the vasoconstrictor component can rarely be associated with feeling very restless. In rare instances, this absorption may also cause an irregular heartbeat (palpitations).

Q: What should I do if I miss a dose of Coldistan?

Official usage instructions permit administration up to four times daily (q.i.d.), requiring an interval of at least four hours between administrations. Official product information does not specify a missed-dose protocol, requiring users to adhere to the maximum allowed frequency and minimum interval between administrations.

Q: Can Coldistan be crushed or chewed?

According to official labeling, Coldistan is a solution intended exclusively for topical application as an ophthalmic (eye) or nasal solution. As it is a solution intended for topical application, it is not formulated to be ingested orally as a tablet, and therefore is not designed to be crushed or chewed.

Q: Has Coldistan been studied in people with liver problems?

Official regulatory documents advise that patients with impaired liver function should use the product with caution. This is because the metabolism of the active ingredients, particularly Diphenhydramine, is primarily handled by the liver.

Q: Does Coldistan have a warning label about kidney function?

Official regulatory documents advise that patients with renal (kidney) dysfunction may be at greater risk for adverse effects from the active ingredients. This is due to the potential for the drug and its metabolites to accumulate in the body.

Q: Is Coldistan gluten-free?

Official labels and prescribing information list all inactive ingredients (excipients). Information regarding the presence of specific allergens like gluten is not universally documented for all formulations; therefore, the specific product packaging must be consulted to confirm excipient details.

Q: Does Coldistan interact with herbal supplements like St. John's Wort?

The official interaction profile is specific to certain prescription and over-the-counter medications. Official regulatory sources state that the evidence base is lacking regarding documented interactions between the active ingredients and many herbal remedies or supplements.

Q: What are the signs of taking too much Coldistan?

Regulatory information warns that in cases of excessive systemic absorption or overuse, the most serious symptoms include significant increases in blood pressure and cardiac arrhythmias. Other documented symptoms include confusion and possibly seizures.

Q: Is the active ingredient in Coldistan addictive?

Regulatory literature notes that the Diphenhydramine component, when taken in high doses beyond its labeled use, has been associated with misuse and chronic abuse for its psychoactive effects. Tolerance to the sedating effect may also develop over time.

Q: Does Coldistan contain any preservatives or dyes that cause reactions?

Official labels and prescribing information list all inactive ingredients (excipients). Due to potential variations in formulation between products, the specific packaging must be consulted to identify all listed preservatives, dyes, or other excipients.

Q: Can Coldistan be taken on an empty stomach?

Coldistan is a solution intended exclusively for topical application to the eye or nose. Since it is not an oral medication, the product's topical use means its systemic absorption and efficacy are not typically affected by stomach contents.

How should Coldistan be stored and disposed of?

Official Storage and Disposal Requirements for Coldistan

Coldistan storage, handling, and disposal guidelines are typically defined by official government regulatory agencies (such as the EMA, FDA, or Health Canada) in the product's SmPC or Prescribing Information. These official documents mandate specific conditions to ensure product stability and safety.

However, publicly available authoritative regulatory records do not contain specific, labeled storage conditions (including required temperature range or protection from light and moisture) or formal disposal instructions for Coldistan.

This means that explicit, state-verified information regarding in-use stability, packaging constraints, and requirements for disposal as hazardous or controlled waste is not publicly documented by major regulatory bodies. Always consult the packaging leaflet or a pharmacist for guidance on keeping the medicine out of reach of children and disposing of unused product according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coldistan found in:

A-Z Index: